<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02773147</url>
  </required_header>
  <id_info>
    <org_study_id>2015-004311-20</org_study_id>
    <nct_id>NCT02773147</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin B on Plasma Neurofilament Light Protein (NFL) in HIV-infected Individuals With Increased Plasma Homocysteine</brief_title>
  <official_title>Effect of Vitamin B Substitution on Plasma NFL and Neurocognitive Performance in HIV-infected Individuals With Increased Plasma Homocysteine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Göteborg University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if B vitamin substitution have effect on NFL&#xD;
      (neurofilament light protein) plasma levels and neurocognitive performance in HIV-infected&#xD;
      individuals with increased plasma homocysteine&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Declining NFL or decreased rate of increase of NFL</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Triobe</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyanocobalamin 0,5 mg. Daily for 24 months. Folate 0,8 mg. Daily for 24 months. Pyridoxine 3,0 mg. Daily for 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyanocobalamin</intervention_name>
    <arm_group_label>Triobe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folate</intervention_name>
    <arm_group_label>Triobe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine</intervention_name>
    <arm_group_label>Triobe</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The ability to understand and give informed consent to participate.&#xD;
&#xD;
          2. HIV-1 infected with stable ART &gt; 12 months&#xD;
&#xD;
          3. Plasma HIV-RNA &lt; 50 copies/ml&#xD;
&#xD;
          4. Plasma homocysteine ≥ 12 μmol/L (subjects with &lt; 12 μmol/L will be included in the&#xD;
             analysis of secondary endpoint 3 (see 5.4).&#xD;
&#xD;
          5. Male or female, age 18 or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with trimethoprim-sulfamethoxazole or methotrexate&#xD;
&#xD;
          2. Ongoing B6, B12 or folate substitution&#xD;
&#xD;
          3. Antiepileptic treatment&#xD;
&#xD;
          4. Small bowel or ventricular resection&#xD;
&#xD;
          5. Disturbed absorption in small bowel (Mb Crohn, untreated coeliac disease)&#xD;
&#xD;
          6. Ongoing neurological disease or severe psychiatric disease&#xD;
&#xD;
          7. Any malignant tumor in the history.&#xD;
&#xD;
          8. Severe ongoing infection or opportunistic infection&#xD;
&#xD;
          9. AUDIT &gt; 7 for men and &gt; 5 for women&#xD;
&#xD;
         10. MADRS &gt; 20&#xD;
&#xD;
         11. Significant B12 or folate deficiency that indicate substitution (all subjects will be&#xD;
             offered adequate substitution, they will be included in the analysis of secondary&#xD;
             endpoint 3 (see 5.4)).&#xD;
&#xD;
         12. Pregnancy at screening visit, or planning pregnancy during study period is an&#xD;
             exclusion criteria. (Not due to toxicity of Triobe, but to elevated risk of being&#xD;
             prescribed B-vitamins outside of trial. If study object gets pregnant during study,&#xD;
             she can continue the study but must be excluded if she starts treatment with other&#xD;
             B-vitamin treatment than Triobe.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magnus Gisslén, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Göteborg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magnus Gisslén, MD, PhD</last_name>
    <phone>+46313436238</phone>
    <email>magnus.gisslen@infect.gu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Infectious Diseases, Sahlgrenska university hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Gisslén, MD, PhD</last_name>
      <phone>+46313436238</phone>
      <email>magnus.gisslen@infect.gu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>December 29, 2017</last_update_submitted>
  <last_update_submitted_qc>December 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

